... from any ideas, methods, instructions or products referred to in the content or advertisements. Superficial bladder cancer Bacillus Calmette-Guérin Intravesical therapy Systemic immunity Original Paper Urol Int 1995;54:137-141 Kemal Sarica Sümer Baltaci Ya§ar Bedük Okan Süzer SahirKiliç Y...

...Ali Erol; Suat Özgür; Murat Basąr; Selahattin Çetin The efficacy and side effects of the prophylactic intravesical bacillus Calmette-Guérin and epirubicin combination therapy were evaluated in 14 patients who underwent transurethral resection for Ta–T1 superficial bladder cancer. Therapy...

...Yoshio Aso; Hideyuki Akazan A randomized controlled study was conducted in patients with superficial bladder cancer in order to investigate the safety of an orally administered (3 g/day) Lactobacillus preparation, biolactis powder (BLP), and its preventive effect on the recurrence after...

... of patients with benign urological diseases and patients with superficial bladder cancer. However, a significant difference exists versus patients with deeply infiltrating carcinomas. 20 patients revealed a loss of ABH antigens on the initial tumor. During the follow-up of at least 1 year, patients...

... Superficial bladder cancer Resorption in the bladder tumor and normal tissue Urol. int. 37: 389-393 (1982) Investigation about the Penetration Depth in the Normal Bladder Wall and Tumor by Local Instillation of Mitomycin into the Urinary Bladder B. Aeikens, R. Niermann, E. Schindler Uroiogische Klinik der...

.... Bacillus Calmette-Guérin Superficial bladder cancer Intravesical immunotherapy Urologia Internationalis Original Paper Urol Int 2008;80:74 79 DOI: 10.1159/000111734 Received: June 15, 2006 Accepted after revision: December 12, 2006 Intravesical Bacillus Calmette-Guérin Therapy for T1 Superficial...

... advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Superficial bladder cancer BCG therapy...

... (p < 0.01). Conclusion: The two doses of mitoxantrone resulted in similar efficacy for the prevention of superficial bladder cancer recurrences, with the dose of 10 mg of mitoxantrone being related to fewer side effects. In comparison with mitoxantrone, the adjuvant intravesical immunotherapy...

... or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Superficial bladder cancer...

.... Alfred Witjesc Departments of aUrology and bPathology, Numune Hospital, Ankara, Turkey, and cDepartment of Urology, University Hospital, Nijmegen, The Netherlands Key Words Superficial bladder cancer W Cytology W Sensitivity Abstract Objective: To improve sensitivity by using different portions of voided...

...Tomoyasu Tsushima; Yoshiyuki Miyaji; Masatoshi Noda; Yasutomo Nasu; Hiromi Kumon; Hiroyuki Ohmori As postoperative adjuvant therapy for superficial bladder cancer, intravesical instillation therapy is commonly conducted. In this case, from the view point of prevention of intraoperative...